Amgen Inc. acquires Nuevolution AB (publ)
On 8 July 2019, Amgen Inc. announced that it completes its recommend public cash offer to the shareholders of Nuevolution AB, listed on Nasdaq Stockholm. The offer was accepted by shareholders representing 97.6 percent of the shares and votes in Nuevolution. The total value of the Offer was approximately SEK 1,610 million.
Nuevolution, with headquarters in Copenhagen, is a small molecule drug discovery platform biotech company. Nuevolution partners its proprietary discovery platform and programs with pharmaceutical and biotechnology companies to seek future benefits for patients in need of novel medical treatment options.
Amgen Inc. is one of the world's leading biotechnology companies, with a vision deeply rooted in innovative science. Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics.
Amgen Inc. was advised by Mannheimer Swartling in the transaction.